Biography

Kevin McCulloch was named President and Chief Operating Officer of Xeris in August 2024.  He joined Xeris Pharmaceuticals in October 2018 as Senior Vice President, Global Operations and Business Development and was named Chief Commercial Officer in September 2021. Mr. McCulloch has spent more than 35 years in the pharmaceutical and medical device industry in diverse leadership and general management roles spanning sales, marketing, and business operations for both US and international entities.

Prior to joining Xeris, Kevin was the President of Global Solutions at Hill-Rom and earlier, as Chief Business Officer for Water Street Healthcare Partners Pharmaceutical Holdings. Mr. McCulloch spent 15 years with Baxter Healthcare in successive management roles including GM/President of the Global Services, Global Fluid Systems (GFS), Infusion Systems (IS), and Fenwal business units. While the leader of GFS, he created Celerity Pharmaceuticals, one of the industry’s first R&D externalization ventures that has since successfully generated multiple new product launches. As leader of the IS business, he oversaw the acquisition and integration of Sigma International into the IS portfolio while successfully navigating the business out of a long-standing consent decree. As the President of Fenwal, a global leader in blood collection and apheresis technology, Mr. McCulloch led its successful divestiture to TPG in 2007. He started his Baxter career as a Vice President of Global Marketing in the Renal division. Prior to Baxter, Mr. McCulloch spent 9 years at GD Searle in roles of increasing responsibility in business development, marketing, and sales. He began his career as a territory sales representative with the Upjohn Company.

Mr. McCulloch holds an MBA from Northwestern University’s Kellogg School of Management and a BS in Biology from the University of Michigan.